Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Advanced Course in Rare Lipid Disorders - (German) from Vienna
About This Webinar
We are delighted to invite you to this EAS Advanced Course in Rare Lipid Disorders, hosted jointly by EAS and Austrian Atherosclerosis Society & Swiss Atherosclerosis Association. Our expert faculty will each give a 20-min presentation on their specialist topic, and following each talk there will be Q&A with the audience.
Please note that the presentations will be in German.
The course is free of charge.
Photo © selvanegra – iStockphoto
--------------------
Willkommen
Liebe Kolleginnen und Kollegen,
Fortschritte in der Molekularen Diagnostik und Therapie haben das Management seltener Lipidstoffwechsel erkrankungen stark verbessert. Dennoch sind Unterdiagnostik und Unterbehandlung häufig, vor allem wegen der großen Variabilität in der klinischen Symptomatik und genetischen Ätiologie.
Um diese Herausforderungen kennenzulernen, laden wir Sie herzlich ein, am Advanced Course Webinar über «Seltene Lipidstoffwechsel-Krankheiten» am 26. November 2021 teilzunehmen. Der Kurs richtet sich an Ärztinnen und Ärzte mit besonderem Interesse für Lipidstoffwechsel-Krankheiten oder seltene Krankheiten und wird unterstützt durch die European Atherosclerosis Society, die Schweizerische und Österreichische Atherosklerosegesellschaften, sowie Alexion. Für das Programm haben renommierte Fachpersonen zugesagt –hierfür, auch an dieser Stelle, vielen Dank.
Die Teilnahme am Kurs ist kostenfrei.
Agenda
- Begrüßung und Einleitung || Welcome and Introduction, Christoph Binder
- HDL-assoziierte Erkrankungen || HDL-related disorders, Arnold von Eckardstein
- Hypobetalipoproteinämie und Homozygote Familiäre Hypercholesterinäme || Hypobetalipoproteinemia and Homozygous FH, Yvonne Winhofer
- Neue Mechanismen der LDL-Rezeptor Regulation: Neue Kandidaten-Gene für Familiäre Hypercholesterinämie? || New memchanisms for LDL regulation, Arnold von Eckardstein
- Extrem erhöhtes Lipoprotein(a) || Extremely elevated lipoprotein(a), Florian Kronenberg
- Familiäres Chylomikronämie Syndrom || Familial Chylomicronemia Syndrome, Thomas Stulnig
- Cholesterin-Ester-Speicher Krankheit || Cholesterol-Ester-Storage Disease, Elmar Aigner
- Sphingolipid-Synthese Störungen || Sphingolipid-Synthesis Disorders, Thorsten Hornemann
- Sphingolipid Speicherkrankheiten || Sphingolipid Storage Diseases , Albina Nowak
- Abschluß || Closing, Arnold von Eckardstein & Christoph Binder
Who can view: Everyone
Webinar Price: Free
Featured Presenters
Prof
Current position: Lead consultant Hepatology, First Department of Medicine, Paracelsus Medical University Salzburg
Current place of work: Universitätsklinikum Salzburg, Austria
Research interests: Metabolic and genetic liver diseases, in particular clinical and genetic aspects of non-alcoholic fatty liver disease
Hobbies: Hiking, skiing, cycling,
Medical career: Elmar Aigner obtained his medical degree from Innsbruck University and received his clinical training in general internal medicine with subsequent specialty training in Gastroenterology and Hepatology, and Lipidology/Metabolic diseases at the University Clinic Salzburg, Austria.
Prof. Aigner has authored and co-authored more than 85 peer-reviewed scientific papers with an impactor >600, >3.000 cites. He is a member of the governing board of the Austrian Society of Gastroenterology & Hepatology and actively involved in lecturing and student education in Salzburg as the Faculty head of Medicine.
Current place of work: Universitätsklinikum Salzburg, Austria
Research interests: Metabolic and genetic liver diseases, in particular clinical and genetic aspects of non-alcoholic fatty liver disease
Hobbies: Hiking, skiing, cycling,
Medical career: Elmar Aigner obtained his medical degree from Innsbruck University and received his clinical training in general internal medicine with subsequent specialty training in Gastroenterology and Hepatology, and Lipidology/Metabolic diseases at the University Clinic Salzburg, Austria.
Prof. Aigner has authored and co-authored more than 85 peer-reviewed scientific papers with an impactor >600, >3.000 cites. He is a member of the governing board of the Austrian Society of Gastroenterology & Hepatology and actively involved in lecturing and student education in Salzburg as the Faculty head of Medicine.
Prof
Th. Hornemann is professor for clinical chemistry and head of research at the Institute for Clinical Chemistry, University Zurich. His primary interest is the sphingolipid metabolism. Prof. Hornemann and his team developed several unique analytical methods and metabolic labelling techniques to investigate the structure, function and metabolism of sphingolipids with a particular focus on rare and bioactive sphingolipid metabolites.
He discovered and characterized a class of atypical and toxic 1-deoxySphinglipids (1-deoxySL) as pathogenic metabolites causing the inherited peripheral neuropathy HSAN1 and also linked 1-deoxySLs to the pathology of the diabetic sensory neuropathy.
He has long-standing experiences in analytical chemistry and LC-HRMS-based lipidomics (targeted and untargeted) and established several lipid metabolites and lipid based metabolic signatures as diagnostic and prospective biomarkers for cardio-metabolic diseases - including NAFLD, CVD, MetS and T2DM.
He discovered and characterized a class of atypical and toxic 1-deoxySphinglipids (1-deoxySL) as pathogenic metabolites causing the inherited peripheral neuropathy HSAN1 and also linked 1-deoxySLs to the pathology of the diabetic sensory neuropathy.
He has long-standing experiences in analytical chemistry and LC-HRMS-based lipidomics (targeted and untargeted) and established several lipid metabolites and lipid based metabolic signatures as diagnostic and prospective biomarkers for cardio-metabolic diseases - including NAFLD, CVD, MetS and T2DM.
Prof
Arnold von Eckardstein studied medicine in Giessen and Kiel and then specialized in laboratory medicine and clinical chemistry in Frankfurt and Münster (Germany). Since 2001, he is professor at the medical faculty of the University of Zurich and the director of the Institute of Clinical Chemistry of the University Hospital of Zurich (Switzerland; http://www.en.ikc.usz.ch/Pages/default.aspx).
His main research interests include risk factors and biomarkers of cardiovascular and metabolic diseases as well as structure, function, and metabolism of high density lipoproteins (HDL) and sphingolipids. He has published about 400 original and review papers in international peer reviewed scientific journals (h-index: 80). Arnold von Eckardstein is the Editor-in-Chief of Atherosclerosis and current member of the Editorial Boards of Arteriosclerosis, Thrombosis and Vascular Biology; BBA Molecular Biology of Lipids; Cardiovascular Research, and European Heart Journal. Previously, he served as the Chairman of the European Lipoprotein Club, the Swiss and German Atherosclerosis Societies, and the Swiss Society of Clinical Chemistry as well as the Secretary of the European Atherosclerosis Society.
His main research interests include risk factors and biomarkers of cardiovascular and metabolic diseases as well as structure, function, and metabolism of high density lipoproteins (HDL) and sphingolipids. He has published about 400 original and review papers in international peer reviewed scientific journals (h-index: 80). Arnold von Eckardstein is the Editor-in-Chief of Atherosclerosis and current member of the Editorial Boards of Arteriosclerosis, Thrombosis and Vascular Biology; BBA Molecular Biology of Lipids; Cardiovascular Research, and European Heart Journal. Previously, he served as the Chairman of the European Lipoprotein Club, the Swiss and German Atherosclerosis Societies, and the Swiss Society of Clinical Chemistry as well as the Secretary of the European Atherosclerosis Society.
Prof
Dr. Nowak is senior clinician, researcher and lecturer at the University Heart Center Zurich.
Her main interest is understanding the disease mechanisms underlying inborn errors of metabolism and particularly Fabry disease. She has been treating the Zurich Fabry disease cohort of over 100 patients for 10 years.
She is a nephrologist and specialist of general internal medicine. Her undergraduate training residency was at the University Hospitals Bern, Basel and Zurich Switzerland as well as at the Royal Sussex Hospital Brighton, UK. Her clinical and scientific research interests also include vitamin D, iron and mineral metabolism. She is currently a Principal Investigator of numerous trials and has authored 48 original research publications and 29 review articles, letters and book chapters.
She is reviewer of several international scientific journals. She also organized and chaired several national and international scientific events.
Her main interest is understanding the disease mechanisms underlying inborn errors of metabolism and particularly Fabry disease. She has been treating the Zurich Fabry disease cohort of over 100 patients for 10 years.
She is a nephrologist and specialist of general internal medicine. Her undergraduate training residency was at the University Hospitals Bern, Basel and Zurich Switzerland as well as at the Royal Sussex Hospital Brighton, UK. Her clinical and scientific research interests also include vitamin D, iron and mineral metabolism. She is currently a Principal Investigator of numerous trials and has authored 48 original research publications and 29 review articles, letters and book chapters.
She is reviewer of several international scientific journals. She also organized and chaired several national and international scientific events.
Prof
Florian Kronenberg received his MD from the University of Innsbruck, Austria. After his training in Medical Genetics in Gerd Utermann's laboratory he worked with Roger R. Williams and Steve Hunt at the Department of Cardiovascular Genetics at the University of Utah, USA. Later, he was the head of the Research Unit "Genetic Epidemiology" at the Institute of Epidemiology, at the Helmholtz Center Munich. In 2004, he became full professor and head of the Institute of Genetic Epidemiology at the Medical University of Innsbruck.
His main research interests are genetic and clinical epidemiological studies on lipoprotein(a) as one of the most important genetic risk factors for cardiovascular disease. His team has probably the largest collection of samples with more than 30.000 individuals with in depth characterization of the LPA gene including data from Western blot analyses. He is Co-Editor of "Atherosclerosis" and served as workgroup member on several guideline and consensus initiatives in the field of kidney disease and lipid metabolism (K/DOQI, KDIGO and EAS).
Florian Kronenberg has published more than 480 papers including 385 original papers and roughly 90 review articles, editorials and book chapters.
His main research interests are genetic and clinical epidemiological studies on lipoprotein(a) as one of the most important genetic risk factors for cardiovascular disease. His team has probably the largest collection of samples with more than 30.000 individuals with in depth characterization of the LPA gene including data from Western blot analyses. He is Co-Editor of "Atherosclerosis" and served as workgroup member on several guideline and consensus initiatives in the field of kidney disease and lipid metabolism (K/DOQI, KDIGO and EAS).
Florian Kronenberg has published more than 480 papers including 385 original papers and roughly 90 review articles, editorials and book chapters.
Prof
Associate Professor of Internal Medicine
Division of Endocrinology and Metabolism
Department of Medicine III
Medical University of Vienna
Division of Endocrinology and Metabolism
Department of Medicine III
Medical University of Vienna
Prof
Clinical Division of Endocrinology & Metabolism
Department of Medicine III
Medical University of Vienna
Department of Medicine III
Medical University of Vienna
Hosted By
Attended
(68)
Recommended